臨牀透析 Vol.27 No.4(2-3)


特集名 透析診療における分子バイオマーカーの新たな展開
題名 [各論― 日常透析診療に役立つ分子バイオマーカー]肝臓病
発刊年月 2011年 04月
著者 葛谷 貞二 武蔵野赤十字病院消化器科
著者 泉 並木 武蔵野赤十字病院消化器科
【 要旨 】 透析患者はC型やB型肝炎ウイルスの合併頻度が高く,透析患者に対するウイルス性肝炎や肝細胞癌のスクリーニングは重要である.HCV抗体やHBs抗原が陽性であった場合,HCV RNAあるいはHBV DNAを測定し感染の有無を確認する.透析患者のALT値は一般的に低値であるが,ウイルス性肝炎を合併した患者ではALT値の上昇が軽度であっても肝臓の炎症や線維化を伴っていることがある.肝細胞癌の腫瘍マーカーにはAFP,AFP-L3,PIVKA-IIの3種があるが,透析患者においても異常値の判定は健常人と同じでよいとされる.これらを定期的に測定することは,肝細胞癌の早期発見,早期治療のために重要である.
Theme New Perspectives of Molecular Biomarker in Dialysis Therapy
Title Useful molecular biomarkers for concerning liver disease in hemodialysis patients
Author Teiji Kuzuya Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
Author Namiki Izumi Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
[ Summary ] Hemodialysis patients exhibit a susceptibility to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections with a higher rate of incidence than the general population. Therefore, it is important for hemodialysis patients that we examine molecular biomarkers for hepatitis virus infections and hepatocellular carcinoma (HCC). First, routine serologic testing for HCV and HBV infection markers should be conducted. HBs-Ag and HCV-AB should be examined regularly also. If HBs-Ag or HCV-AB tests are positive, HCV-RNA or HBV-DNA should be examined to diagnose viral hepatitis. Generally, the level of serum alanine aminotranferase (ALT) in hemodialysis patients is lower than that in the general population. However, even if the level of serum ALT shows mild abnormalities in hemodialysis patients with chronic hepatitis infection, these patients may have accompanying inflammation and/or liver fibrosis. The tumor markers indicating HCC are alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and proteins induced by lack of vitamin K or antagonist-II (PIVKA-II). Normal ranges of these three tumor markers in hemodialysis patients are the same as those observed in the general population. It is important for early detection of the development of liver cirrhosis or the occurrence of HCC that we examine these molecular biomarkers regularly even if hemodialysis patients have no symptoms.
戻る